Axitinib Powder

Product Details

Axitinib is a small molecule tyrosine kinase inhibitor effective against multiple targets, including VEGF receptors 1, 2 and 3, Kit, PDGFR (multi-targeted, anti-angiogenesis-based small molecule inhibitor. Axitinib powder blocks the action of certain proteins called kinases that play a role in tumor growth and metastasis. This period of Unprecedented levels of temporal drug development have dramatically changed the treatment paradigm for metastatic renal cell carcinoma and provide patients with multiple treatment options.

Axitinib powder is a multi-targeted small molecule inhibitor, the main targets are VEGFR, Kit, PDGFR, RET. The currently approved indication for the market is the second-line treatment of advanced renal cancer, that is to say, after the failure of Sutent treatment, API axitinib powder can be selected for treatment of advanced renal cancer. In addition to renal cancer, this drug has also been tried by patients for liver cancer, sarcoma, neuroendocrine tumors and other solid tumors that are relatively sensitive to anti-angiogenic drugs and have a rich tumor blood supply.

Health Benefits

The currently approved indication for the market is the second-line treatment of advanced renal cancer, which means that axitinib can be selected for advanced renal cancer after the failure of Sutent treatment. In addition to renal cancer, this drug has also been tried by patients for liver cancer, sarcoma, neuroendocrine tumors and other solid tumors that are generally sensitive to anti-angiogenic drugs and have a rich tumor blood supply, and it also has a certain curative effect.

Axitinib is an antineoplastic drug used clinically for adult patients with advanced renal cell carcinoma (RCC) who have previously failed a tyrosine kinase inhibitor or cytokine therapy.